Table 3

Results from Phase II studies of patients with NSCLC treated with gefitiniba

Trial end pointIDEAL-1IDEAL-2
250 mg/day (n = 103)500 mg/day (n = 105)250 mg/day (n = 102)500 mg/day (n = 114)
Objective tumor response, %18.419.011.88.8
Symptom improvement, %40.33743.135.1
Disease control, %54.451.443.035.0
Overall survival, mo7.67.96.16.0
  • a See Refs. 3 , 4 .